Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

221 / 244

PJ-35
Elucidating pharmacological beneficial functions of soybean
extract on metabolism
Hiroko OKUNO 1*, Licht MIYAMOTO1, Rie TAKAHASHI1,
Koichiro TSUCHIYA 1. 1Dept. of medical Pharmacology, Inst. of
Biomedical Sciences, Tokushima University Graduate School., Japan
According to the Standard Tables of Food Composition in
Japan, soybean contains protein (33%), carbohydrates (28%),
lipids (19%), water (13%) and ash content (5%). Some ingre-
dients of soybean have been reported to provide such
beneficial effects as hypotensive activity, prevention of
obesity, proliferation of lactobacillus bifidus, attenuation of
osteoporosis and antioxidative action. Therefore, soybean has
attractedourattentionas anexcellent functional food. Soybean
is processed into various foods such as tofu, soy milk and soy
sauce, as well as soybean oil, feedstuffs and fertilizer, and
they have been used all over theworld. For example, soymilk is
a good alternative to cow ’s milk for vegetarians, lactose-
intolerant people and consumers allergic to cow ’s milk thanks
to its high-quality proteins and essential fatty acids with low
amount of cholesterol, gluten or lactose. In Japan, consump-
tion of soy milk was greatly increased from 2007 to 2012. Thus,
not only soybean but also soy products are attracting much
attention in recent years. Furthermore, it has been reported
that an effect of suppressing cancer cell growth in components
contained in soybean or soy products.
In this study, we examined the effect of soy extract in the
experiments in vitro and in vivo for the purpose of elucidating
pharmacological beneficial functions of soybean. The soy
extract were administered orally at 100 mg/kg/day for 4 weeks
to male ddY mice, and we measured body weight, food and
water intake. We examined the glucose uptake activity of
extract from soybean by using [3H]2-deoxy-D-glucose in
myotube differentiated from C2C12 cells. In addition, we
studied the expression levels of glucose uptake-related
factors by Western Blotting. The body weight was decreased
in the group of the extract from soybean compared to the
control group, while food and water intake were almost same
between groups. Further, soy extract increased the glucose
uptake in a concentration-dependent manner in the myotube.
However, the phosphorylation level of Akt and AMPK had not
changed significantly. As a result, the extract of soybean
induced weight loss and enhancement of glucose uptake in
cultured cells as well as in vivo. Although the mechanism
remains unknown, it is suggested that the extract of soybean
has an anti-diabetic effect which may be independent of the
Akt or AMPK.
PJ-36
Long term DPP4i use reduces joint pain in patients with type 2
diabetes. A study using the national health insurance
Shih Jung YEN 1,4, Yu Han CHANG1, Mei Yueh LEE2,4 ,
Pi Jung HSIAO 3,4, Deng Chyang WU 1, Shyi Jang SHIN3,4,
Kun Der LIN 1,4*. 1Kaohsiung Municipal Ta-Tung Hospital,
2 Kaohsiung Municipal Hsiaokang Hospital, 3Kaohsiung Medical
Unerversity Chung-Ho Memorial Hospital, 4Division of
Endocrinology and Metabolism, Taiwan
Objective: The link between arthropathy in type 2 diabetes
patients treated with DPP4 inhibitors (dipeptidyl peptidase 4
inhibitors) is rarely studied in Asians.
Research design and methods: A random sample of 1,000,000
subjects between January 1 2009 and December 31 2010
covered by the National Health Insurance Research Database
(NHIRD) in 2000 was recruited. A total of 19,729 diabetes, type 2
patients who received oral anti-diabetic agents at least for
3 months or hospitalization with the diagnosis of Diabetes
mellitus without joint pain were followed for 1 year. The
definition of who received sitagliptin was patient with
Sitagliptin use at least 1 month. There are 2,825 patients
who received Sitagliptin and the other never used Sitagliptin.
We used 1:3 for all comorbidities matching: 2,813 of Diabetes
patients received Sitagliptin followed up till the end of study
and 82 patients had the episode of joint pain (2.9%). On the
other hand, 8,616 of Diabetes patients without using
Sitagliptin followed up till the end of study and 315 patients
had the episode of joint pain (3.7%).
Results: Under sitagliptin use, arthralgia appeared early after
initiation of treatment: Cumulative defined daily dose
(DDD) < 84. The risk of joint pain didn’t increase significantly
under Sitagliptin use followed up for 1 year. On the contrary,
joint pain significantly decreased under Sitagliptin use
(P < 0.001).
Conclusions: Its meaning of no increase of nonsteroidal anti-
inflammatory drugs(NSAIDs) under sitagliptin use, on the
contrary, NSAIDs cumulative DDDs significantly decreased
after sitagliptin use within 1 year, the probable explanation
may be under sitagliptin use, its exerts an anti-inflammatory
action (1). If indeed DPP-IV and CD26 are proinflammatory,
their inhibitors, like sitagliptin, could potentially be anti-
inflammatory and possibly anti-atherogenic because athero-
sclerosis is a chronic inflammation of the arterial wall. Thus,
sitagliptin may offer anti-inflammatory effect.
PJ-38
Congenital malformations in the first offspring of women with
gestational diabetes mellitus in Taiwan – a nationwide survey
Chien-Ning HUANG1,2, Ying-Hsiang CHOU3 , Jia-Yuh CHEN4,5,
Pen-Hua SU4,5, Chih-Jen TSENG6 , Yung-Po LIAW7,
Ya-Fang TSAI8, Yi-Chang LI 8, Ting-Huan CHANG8,
Charles Tzu-Chi LEE9, Suh-Jen CHEN4,10, Cheng-Hung LIN11 ,
Guan-Ming CHEN5, Pei-Syuan CHIANG5, Ting-Yi TSAI8,
Jeng-Yuan CHIOU8*. 1Endocrinology and Metabolism, Chung Shan
Medical University Hospital, 2Institute of Medicine, Chung Shan
Medical University, 3School of Medical Imaging and Radiological
Sciences, Chung Shan Medical University, 4Department of Pediatrics,
Chung Shan Medical University Hospital, 5Department of Pediatrics,
School of Medicine, Chung Shan Medical University, 6Department of
Obstetrics and Gynecology, Chung Shan Medical University Hospital,
7Department of Public Health and Institute of Public Health, Chung
Shan Medical University, 8School of Health Policy and Management,
Chung Shan Medical University, Taichung, 9Department of Health
Promotion and Health Education, National Taiwan Normal
University, Taipei, 10School of Nursing, Chung Shan Medical
University, 11Information Center, Chung Shan Medical University
Hospital, Taichung, Taiwan
Background: Recent literatures have shown that gestational
diabetes mellitus (GDM) associated with the occurrence of
congenital malformations (CMs) in their offspring. However
the results were controversial. In Taiwan very few studies have
been conducted in this regard.
Objective: This study aimed to analyze the CMs and health
status of the first offspring from mothers with GDM using a
national representative. The relation to different manage-
ments during pregnancy on the risk of CMs was also
investigated.
Method: The dataset was obtained from the Birth Certificate
Application, National Health Insurance Research Database,
and the Birth Registration database during 2004 to 2009. Those
who had delivered newborns (n = 188,798) before 2004, and
those who have already been suffering from diabetes prior to
pregnancy (n = 3,356) were excluded. A total 19,430 pregnant
women with GDM were recruited for analysis, of whom 793
women were on insulin treatment while the remaining 18,637
women on diet control during their pregnancy.
Results: The prevalence of GDM in Taiwan is about 3.4% of
the total 1st-preganant women. Among 19,430 GDM mothers,
the average age was 31 years old, the average gestational age
38.3 weeks and the average birth weight of their offspring was
3,163 gm. When adjust for mother age, gestational weeks,
urbanization, and CCI, the results showed that GDM mother
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S203